$-0.76 EPS Expected for Syndax Pharmaceuticals, Inc. (SNDX)

October 13, 2018 - By Ellis Scott

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Logo

Analysts expect Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report $-0.76 EPS on November, 6.They anticipate $0.08 EPS change or 11.76 % from last quarter’s $-0.68 EPS. After having $-0.74 EPS previously, Syndax Pharmaceuticals, Inc.’s analysts see 2.70 % EPS growth. The stock decreased 2.59% or $0.17 during the last trading session, reaching $6.39. About 202,142 shares traded. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has declined 44.11% since October 14, 2017 and is downtrending. It has underperformed by 59.73% the S&P500.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $149.24 million. The company's lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

More recent Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news were published by: Seekingalpha.com which released: “Syndax Pharma down 12% after hours on updated mid-stage data on entinostat/pembrolizumab combo in lung cancer” on September 24, 2018. Also Benzinga.com published the news titled: “46 Biggest Movers From Friday” on October 01, 2018. Streetinsider.com‘s news article titled: “Pre-Open Movers 09/25: (ASNA) (TLRY) (NIHD) Higher; (TGTX) (OPNT) (SNDX) Lower (more…)” with publication date: September 25, 2018 was also an interesting one.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News